ALK and non-small cell lung carcinoma: To evaluate TD of crizotinib, and investigate the relationship between TD and PFS1, PFS2, OS in a large cohort of patients with advanced ALK‐positive NSCLC who received crizotinib, we conducted a single‐center, retrospective, real‐world cohort study and reported the exploratory outcomes.